FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938353934> ?p ?o ?g. }

• W2938353934 endingPage "81" @default.
• W2938353934 startingPage "73" @default.
• W2938353934 abstract "Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ineligible for the pivotal IMvigor211 phase 3 trial of atezolizumab.To determine the safety and efficacy of atezolizumab in an international real-world setting.Between November 2016 and March 2018 (median follow-up 12.7mo), 1004 patients with locally advanced or metastatic urothelial or nonurothelial urinary tract carcinoma who experienced progression during or after one to three prior therapies for inoperable, locally advanced, or metastatic disease were enrolled. Patients with renal impairment, treated central nervous system metastases, or stable controlled autoimmune disease were eligible; 10% had Eastern Cooperative Oncology Group performance status (ECOG PS) 2 and 98% were platinum pretreated (Clinicaltrials.gov: NCT02928406).Atezolizumab 1200mg every 3wk until progression or unacceptable toxicity.The primary endpoint was safety. Secondary efficacy endpoints included overall survival (OS), progression-free survival (PFS), and overall response rate (ORR).The median treatment duration was 2.8mo (range 0-19); 22% remained on treatment and 8% discontinued because of toxicity. Grade ≥3 adverse events occurred in 45% of patients. The most common grade ≥3 treatment-related adverse events were fatigue, asthenia, colitis, and hypertension (each in 1%). Median OS was 8.7mo (95% confidence interval [CI] 7.8-9.9). The 6-mo OS rate was 60% (95% CI 57-63%), median PFS was 2.2mo (95% CI 2.1-2.4), and the ORR was 13% (95% CI 11-16%; 3% complete responses). Among IMvigor211-like patients (excluding ECOG PS 2 and other IMvigor211 exclusion criteria), median OS was 10.0mo (95% CI 8.8-11.9) and 6-mo OS was 65% (95% CI 61-69%).SAUL confirms the tolerability of atezolizumab in a real-world pretreated population with urinary tract carcinoma. Efficacy overall and in the IMvigor211-like subgroup is consistent with previous pivotal anti-PD-L1/PD-1 urothelial carcinoma trials. These results support the use of atezolizumab in urinary tract carcinoma, including patients with limited treatment options.In this international study we investigated the efficacy and safety of atezolizumab treatment for advanced urinary tract cancer in a large population of pretreated patients, including those who would not normally be candidates for clinical trials. Patients tolerated the treatment well, even if they had autoimmune disease, were being treated with corticosteroids, or had disease that had spread to their brain. Life expectancy in this study for patients typical of everyday clinical practice was similar to that seen in trials that enrolled only selected fitter patients." @default.
• W2938353934 created "2019-04-25" @default.
• W2938353934 creator A5000094560 @default.
• W2938353934 creator A5004985848 @default.
• W2938353934 creator A5010990966 @default.
• W2938353934 creator A5012800133 @default.
• W2938353934 creator A5014807748 @default.
• W2938353934 creator A5016971686 @default.
• W2938353934 creator A5024147987 @default.
• W2938353934 creator A5027991868 @default.
• W2938353934 creator A5033351253 @default.
• W2938353934 creator A5033521569 @default.
• W2938353934 creator A5036620887 @default.
• W2938353934 creator A5045869380 @default.
• W2938353934 creator A5051508644 @default.
• W2938353934 creator A5055824195 @default.
• W2938353934 creator A5071060598 @default.
• W2938353934 creator A5072151730 @default.
• W2938353934 creator A5074987624 @default.
• W2938353934 creator A5079748913 @default.
• W2938353934 creator A5080181504 @default.
• W2938353934 creator A5090663639 @default.
• W2938353934 date "2019-07-01" @default.
• W2938353934 modified "2023-10-16" @default.
• W2938353934 title "Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract" @default.
• W2938353934 cites W1971208896 @default.
• W2938353934 cites W1994993231 @default.
• W2938353934 cites W2009720434 @default.
• W2938353934 cites W2022495797 @default.
• W2938353934 cites W2028376975 @default.
• W2938353934 cites W2068523052 @default.
• W2938353934 cites W2113964885 @default.
• W2938353934 cites W2529206793 @default.
• W2938353934 cites W2531040620 @default.
• W2938353934 cites W2559804019 @default.
• W2938353934 cites W2588916311 @default.
• W2938353934 cites W2592187743 @default.
• W2938353934 cites W2732321180 @default.
• W2938353934 cites W2777192533 @default.
• W2938353934 cites W2792699081 @default.
• W2938353934 cites W2792994866 @default.
• W2938353934 cites W2888599070 @default.
• W2938353934 cites W2889605632 @default.
• W2938353934 cites W2889691772 @default.
• W2938353934 cites W2899953288 @default.
• W2938353934 cites W2901341811 @default.
• W2938353934 doi "https://doi.org/10.1016/j.eururo.2019.03.015" @default.
• W2938353934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30910346" @default.
• W2938353934 hasPublicationYear "2019" @default.
• W2938353934 type Work @default.
• W2938353934 sameAs 2938353934 @default.
• W2938353934 citedByCount "102" @default.
• W2938353934 countsByYear W29383539342019 @default.
• W2938353934 countsByYear W29383539342020 @default.
• W2938353934 countsByYear W29383539342021 @default.
• W2938353934 countsByYear W29383539342022 @default.
• W2938353934 countsByYear W29383539342023 @default.
• W2938353934 crossrefType "journal-article" @default.
• W2938353934 hasAuthorship W2938353934A5000094560 @default.
• W2938353934 hasAuthorship W2938353934A5004985848 @default.
• W2938353934 hasAuthorship W2938353934A5010990966 @default.
• W2938353934 hasAuthorship W2938353934A5012800133 @default.
• W2938353934 hasAuthorship W2938353934A5014807748 @default.
• W2938353934 hasAuthorship W2938353934A5016971686 @default.
• W2938353934 hasAuthorship W2938353934A5024147987 @default.
• W2938353934 hasAuthorship W2938353934A5027991868 @default.
• W2938353934 hasAuthorship W2938353934A5033351253 @default.
• W2938353934 hasAuthorship W2938353934A5033521569 @default.
• W2938353934 hasAuthorship W2938353934A5036620887 @default.
• W2938353934 hasAuthorship W2938353934A5045869380 @default.
• W2938353934 hasAuthorship W2938353934A5051508644 @default.
• W2938353934 hasAuthorship W2938353934A5055824195 @default.
• W2938353934 hasAuthorship W2938353934A5071060598 @default.
• W2938353934 hasAuthorship W2938353934A5072151730 @default.
• W2938353934 hasAuthorship W2938353934A5074987624 @default.
• W2938353934 hasAuthorship W2938353934A5079748913 @default.
• W2938353934 hasAuthorship W2938353934A5080181504 @default.
• W2938353934 hasAuthorship W2938353934A5090663639 @default.
• W2938353934 hasBestOaLocation W29383539341 @default.
• W2938353934 hasConcept C121608353 @default.
• W2938353934 hasConcept C126322002 @default.
• W2938353934 hasConcept C126894567 @default.
• W2938353934 hasConcept C141071460 @default.
• W2938353934 hasConcept C143998085 @default.
• W2938353934 hasConcept C197934379 @default.
• W2938353934 hasConcept C203092338 @default.
• W2938353934 hasConcept C2775949291 @default.
• W2938353934 hasConcept C2777701055 @default.
• W2938353934 hasConcept C2780030458 @default.
• W2938353934 hasConcept C2780352672 @default.
• W2938353934 hasConcept C2908647359 @default.
• W2938353934 hasConcept C2911057145 @default.
• W2938353934 hasConcept C3019882237 @default.
• W2938353934 hasConcept C31760486 @default.
• W2938353934 hasConcept C535046627 @default.
• W2938353934 hasConcept C71924100 @default.
• W2938353934 hasConcept C99454951 @default.
• W2938353934 hasConceptScore W2938353934C121608353 @default.

• next